Quantum Genomics Logo

Quantum Genomics

ALQGC | PA

Overview

Corporate Details

ISIN(s):
FR0010783837 (+4 more)
LEI:
969500TFCD8K9RPM9K97
Country:
France
Address:
6 RUE CAMBACERES, 75008 PARIS
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Quantum Genomics is a biopharmaceutical company that has historically specialized in the research and development of a new class of drugs for cardiovascular diseases, particularly resistant hypertension and heart failure. The company's core innovation was based on Brain Aminopeptidase A Inhibition (BAPAI), a novel mechanism targeting the brain to regulate blood pressure, with firibastat as its lead drug candidate. Following a strategic reorientation in 2024, Quantum Genomics acquired ExactCure, a company developing a digital twin solution. This technology aims to simulate drug effects in individual patients to optimize dosage, personalize treatments, and prevent adverse drug interactions, shifting the company's focus towards personalized medicine and digital health solutions.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Quantum Genomics. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-13 18:00
Post-Annual General Meeting Information
Report de l'Assemblée Générale Mixte du 30/06/2025
French 116.4 KB
2025-04-30 20:00
Earnings Release
Quantum Genomics publishes its 2024 annual financial statements and announces a…
English 206.5 KB
2025-04-30 20:00
Delisting Announcement
Quantum Genomics publie ses comptes annuels 2024 et annonce un changement de li…
French 254.0 KB
2025-04-08 08:00
Delisting Announcement
Quantum Genomics fait un point sur sa situation
French 688.8 KB
2025-04-08 08:00
Delisting Announcement
Quantum Genomics provides an update on its situation
English 626.0 KB
2024-10-29 18:00
Earnings Release
Quantum Genomics publie ses résultats du 1er semestre 2024 et annonce la nomina…
French 241.2 KB
2024-09-27 08:00
Legal Proceedings Report
Quantum Genomics sécurise un financement avec le fonds Akkadian Partners Fund e…
French 74.5 KB
2024-09-04 18:00
Legal Proceedings Report
Quantum Genomics reviewed its financial situation and announced that it has fil…
English 175.5 KB
2024-09-04 18:00
Legal Proceedings Report
Quantum Genomics fait un point sur sa situation financière et annonce qu'elle a…
French 150.0 KB
2024-07-03 13:00
Capital/Financing Update
BILAN SEMESTRIEL S1 DU CONTRAT DE LIQUIDITE CONTRACTE AVEC LA SOCIETE DE BOURSE…
French 275.3 KB
2024-03-13 18:00
Business and Financial Review
Quantum Genomics publie ses résultats de l'exercice 2023. Le rapprochement avec…
French 193.8 KB
2024-03-13 18:00
Earnings Release
Quantum Genomics publishes its results for the 2023 financial year. The merger …
English 166.3 KB
2024-01-10 16:35
Capital/Financing Update
Bilan au 29 décembre 2023 du contrat de liquidité contracté avec la Société de …
English 297.2 KB
2024-01-10 16:30
Capital/Financing Update
Bilan au 29 décembre 2023 du contrat de liquidité contracté avec la Société de …
English 297.2 KB
2023-12-14 18:05
Regulatory News Service
Quantum Genomics enters into exclusive negotiations with ExactCure
English 286.1 KB

Automate Your Workflow. Get a real-time feed of all Quantum Genomics filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Quantum Genomics via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
THERACRYF PLC Logo
Developing sulforaphane-based therapeutics for oncology and behavioural brain disorders.
United Kingdom TCF
Theranexus Logo
Biopharma developing drug candidates for rare neurological diseases like Batten disease.
France ALTHX
TME Pharma N.V. Logo
Clinical-stage biotech developing TME-targeting therapies for aggressive cancers.
Germany ALTME
Toleranzia AB Logo
Developing immune therapies for rare autoimmune diseases like myasthenia gravis.
Sweden TOL
Transgene Logo
Clinical-stage biotech using viral vectors for cancer vaccines and oncolytic viruses.
France TNG
Tvardi Therapeutics Inc. Logo United States of America TVRD
UCAR Logo
A nonprofit consortium managing atmospheric research and providing resources to the scientific community.
France ALUCR
Hong Kong N/A
Urteste S.A. Logo
Developing non-invasive urine tests for early detection & monitoring of multiple cancers.
Poland URT
VALIRX PLC Logo
Developing early-stage therapeutics & diagnostics for oncology and women's health.
United Kingdom VAL